Why Cullinan Therapeutics, Inc.’s (CGEM) Stock Is Down 5.39%
As of Thursday, September 24, Cullinan Therapeutics, Inc.’s CGEM share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. CGEM
$15.23
0.28
1.87%
September 29, 2026 4:00:00 PM
EST
Volume: 1,244,412
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Cullinan Therapeutics, Inc.’s (CGEM) Stock Is Down 6.78%
As of Wednesday, September 23, Cullinan Therapeutics, Inc.’s CGEM share price has dipped by 6.78%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Cullinan Therapeutics, Inc.’s (CGEM) Stock Is Down 11.68%
As of Wednesday, September 23, Cullinan Therapeutics, Inc.’s CGEM share price has dipped by 11.68%, which has investors questioning if this is right time to buy.Tudor Pop
Why Cullinan Therapeutics, Inc.’s (CGEM) Stock Is Up 5.33%
As of Friday, August 21, Cullinan Therapeutics, Inc.’s CGEM share price has surged by 5.33%, which has investors questioning if this is right time to sell.Michael Rose
Why Cullinan Therapeutics, Inc.’s (CGEM) Stock Is Up 5.35%
As of Tuesday, August 04, Cullinan Therapeutics, Inc.’s CGEM share price has surged by 5.35%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | CGEM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $980.1 | $255.7 | 45% |
|
| Shares Out (Mil) | 61.5 | 54.2 | 52% |
|
| Institutional Ownership | 98.6% | 93.1% | 80% |
|
| Float (Mil) | 48.1 | 41.4 | 46% |
|
| Beta | 0.02 | 0.95 | 7% |
|
| Avg Daily Volume (000s) | 1,582 | 706 | 76% |
|
| Price Change (52-week) |
155.5% | 50.7% | 97% |
|
| Growth | CGEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (33.5%) | (10.1%) | 12% |
|
| EPS (5yr) | (7.4%) | 15.8% | 23 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (55.7%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.844) | ($3.135) | ($2.747) | |
| Month Ago EPS | ($0.848) | ($3.165) | ($2.710) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.862) | ($2.998) | ($2.527) | |
| Year/Year Chg | 4.2% | (15.8%) | (22.7%) | |
| Financials | CGEM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($205) | ($44) | 6% |
|
| EPS (TTM) | ($3.469) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($159) | ($32) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $2 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $1,042 | $174 | 41% |
|
| Valuation | CGEM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.05 | 2.50 | 67% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CGEM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.8% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (46.3%) | (47.6%) | 12% |
|
| ROE | (50.3%) | (54.9%) | 15% |
|
| Liabilities to Assets | 11.6% | 29.3% | 7% |
|
| F-Score | 1 | 3 | 1% |
|
Cullinan Therapeutics, Inc. did not pass any screens on 9/29/2026.
